Summit Therapeutics Inc.

SMMT

US86627T1088

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-07-17 EDT			5-day change	1st Jan Change
9.31 ^USD	+2.08%		+12.30%	+256.70%

07-01	Summit Therapeutics Inc.(NasdaqGM:SMMT) added to Russell Small Cap Comp Value Index	CI
07-01	Summit Therapeutics Inc.(NasdaqGM:SMMT) dropped from Russell Microcap Growth Index	CI

Summit Therapeutics plc Announces Resignation of David Roblin as Chief Operating Officer, Chief Medical Officer and President of R&D, Effective 31 January 2020

January 24, 2020 at 07:00 am

Summit Therapeutics plc announced that Dr. David Roblin has resigned as Chief Operating Officer, Chief Medical Officer and President of R&D, effective 31 January 2020.

Latest news about Summit Therapeutics Inc.

Summit Therapeutics Inc.(NasdaqGM:SMMT) added to Russell Small Cap Comp Value Index	06-30	CI
Summit Therapeutics Inc.(NasdaqGM:SMMT) dropped from Russell Microcap Growth Index	06-30	CI
Summit Therapeutics Inc.(NasdaqGM:SMMT) added to Russell 3000 Value Index	06-30	CI
Summit Therapeutics Inc.(NasdaqGM:SMMT) dropped from Russell Microcap Index	06-30	CI
Summit Therapeutics Inc.(NasdaqGM:SMMT) added to Russell 2500 Value Index	06-30	CI
Summit Therapeutics Inc.(NasdaqGM:SMMT) added to Russell 2000 Value Index	06-30	CI
Summit Therapeutics Inc.(NasdaqGM:SMMT) dropped from Russell 3000E Growth Index	06-30	CI
Summit Therapeutics Inc.(NasdaqGM:SMMT) added to Russell 3000E Value Index	06-30	CI
Summit Therapeutics Inc.(NasdaqGM:SMMT) dropped from Russell 3000E Index	06-30	CI
Summit Therapeutics Inc. Enters into Two Sublease Agreements with Genius 24C Inc. and Duggan Investments Research LLC	06-27	CI
Summit Therapeutics Inc. Appoints Jeff Huber to Its Board of Directors	06-27	CI
Akebia Therapeutics, Inc. Appoints Erik Ostrowski as Senior Vice President and Chief Business Officer	06-24	CI
Akebia Therapeutics, Inc. Appoints Erik Ostrowski as Chief Financial Officer	06-24	CI
Summit Therapeutics Inc. announced that it has received $199.999998 million in funding from Baker Bros. Advisors LP	06-17	CI
Summit Therapeutics Inc. Announces Resignation of Ujwala Mahatme as Member of its Board	06-13	CI
Sector Update: Health Care Stocks Steady Premarket Monday	06-03	MT
Stifel Adjusts Summit Therapeutics Price Target to $14 From $8, Maintains Buy Rating	06-03	MT
Transcript : Summit Therapeutics Inc. - Special Call	06-03
Summit Therapeutics Generates $200 Million Through Share Sale; Expand License Territories for Ivonescimab	06-03	MT
Summit Therapeutics Inc. Expands License Territories for Ivonescimab	06-03	CI
Summit Therapeutics Inc. announced that it expects to receive $199.999998 million in funding from Baker Bros. Advisors LP	06-02	CI
Sector Update: Health Care Stocks Flat to Higher Pre-Bell Friday	05-31	MT
Wall Street Set to Open Modestly Higher Friday as Key Inflation Data Meets Expectations	05-31	MT
Sector Update: Health Care	05-31	MT
US Futures Trend Modestly Lower Pre-Bell Friday as Investors Await Key Inflation Report	05-31	MT

Chart Summit Therapeutics Inc.

Duration

Period

More charts

Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.

Sector

Biotechnology & Medical Research

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

7.039 GBP

Average target price

10.58 GBP

Spread / Average Target

+50.32%

Consensus

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SUMMIT THERAPEUTICS INC.	+256.70%	6.4B
VERTEX PHARMACEUTICALS INCORPORATED	+20.03%	126B
REGENERON PHARMACEUTICALS, INC.	+23.61%	118B
ARGENX SE	+23.26%	27.87B
BIONTECH SE	-18.07%	20.95B
GENMAB A/S	-15.13%	16.92B
BEIGENE, LTD.	-14.81%	16.18B
NEUROCRINE BIOSCIENCES, INC.	+9.78%	14.84B
WUXI APPTEC CO., LTD.	-46.10%	14.79B
SAREPTA THERAPEUTICS, INC.	+52.34%	14.08B

Bio Therapeutic Drugs

Summit Therapeutics Inc.

Equities

SMMT

US86627T1088

Biotechnology & Medical Research

Summit Therapeutics plc Announces Resignation of David Roblin as Chief Operating Officer, Chief Medical Officer and President of R&D, Effective 31 January 2020

Latest news about Summit Therapeutics Inc.

Chart Summit Therapeutics Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

Quarterly revenue - Rate of surprise

Sector Bio Therapeutic Drugs